Bristol Myers Squibb claims historic EU win with frontline lymphoma approval
Bristol Myers Squibb (NYSE:BMY) secured a major regulatory milestone on Monday as the European Commission approved its blockbuster immunotherapy Opdivo in combination with chemotherapy for patients fighting advanced blood cancer.
The decision establishes the first-ever immunotherapy-based regimen available in the European Union for newly diagnosed advanced classical Hodgkin Lymphoma.
The clearance specifically covers the use of Opdivo (nivolumab) alongside doxorubicin, vinblastine, and dacarbazine (AVD) to treat adult and adolescent patients aged 12 and older with previously untreated Stage III or IV disease.
The pan-European green light follows hot on the heels of the U.S. Food and Drug Administration's approval of the identical frontline regimen in March 2026, solidifying a global shift toward deploying targeted immune therapies much earlier in a patient's care pathway.
The European Commission based its widespread approval on compelling data from the pivotal Phase 3 SWOG 1826 clinical trial.
In the study, the Opdivo-AVD combination demonstrated a massive 58% reduction in the risk of disease progression or death compared to the previous standard-of-care regimen containing brentuximab vedotin plus AVD.
The survival advantage proved highly statistically significant, establishing a definitive new benchmark for progression-free survival (PFS)—the length of time a patient lives without their cancer worsening.
Longer-term data further supported the regimen's therapeutic durability.
After a median follow-up period of 36.7 months, the overall survival metric had not yet been reached in either treatment group due to high response rates.
However, tracking deaths revealed a stark separation between the arms: only nine deaths occurred among patients receiving the Opdivo combination, compared to 17 deaths in the standard chemotherapy arm.
The newly authorized treatment regimen is immediately valid across all 27 member states of the European Union, alongside Iceland, Liechtenstein, and Norway.